Integrins in cancer: Emerging mechanisms and therapeutic opportunities.

[1]  N. Bonifaci,et al.  Oxidative stress‐induced FAK activation contributes to uterine serous carcinoma aggressiveness , 2022, Molecular oncology.

[2]  Mark D Anderson,et al.  Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Kuppen,et al.  Integrin regulation by tissue factor promotes cancer stemness and metastatic dissemination in breast cancer , 2022, Oncogene.

[4]  E. Brzozowska,et al.  Integrin Alpha v Beta 6 (αvβ6) and Its Implications in Cancer Treatment , 2022, International journal of molecular sciences.

[5]  Zhenzhen Xie,et al.  Integrin-mediated cancer progression as a specific target in clinical therapy. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  Qianqian Jin,et al.  3D matrix promotes cell dedifferentiation into colorectal cancer stem cells via integrin/cytoskeleton/glycolysis signaling , 2022, Cancer science.

[7]  R. Kalluri,et al.  Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. , 2022, Cancer cell.

[8]  S. Loi,et al.  Alpelisib monotherapy for PI3K-altered, pre-treated advanced breast cancer: a phase 2 study. , 2022, Cancer discovery.

[9]  T. Yen,et al.  MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin/FAK/Src/ERK/β-catenin pathway , 2022, Journal of Biomedical Science.

[10]  D. Kwong,et al.  Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma , 2022, Journal of Experimental & Clinical Cancer Research.

[11]  X. Yang,et al.  Deubiquitinating enzyme USP9X regulates metastasis and chemoresistance in triple‐negative breast cancer by stabilizing Snail1 , 2022, Journal of cellular physiology.

[12]  Liming Ge,et al.  Blockade of integrin signaling reduces chemotherapy-induced premature senescence in collagen cultured bladder cancer cells , 2022, Precision clinical medicine.

[13]  Dustin A Cobb,et al.  Targeting of the alphav beta3 integrin complex by CAR-T cells leads to rapid regression of diffuse intrinsic pontine glioma and glioblastoma , 2022, Journal for ImmunoTherapy of Cancer.

[14]  D. Hedley,et al.  A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma , 2022, Journal of gastrointestinal oncology.

[15]  D. Hanahan.  Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[16]  C. Bailly,et al.  Molecular docking study of britannin binding to PD-L1 and related anticancer pseudoguaianolide sesquiterpene lactones , 2021, Journal of Receptor and Signal Transduction Research.

[17]  D. Sheppard,et al.  Regulatory T cells promote cancer immune-escape through integrin αvβ8-mediated TGF-β activation , 2021, Nature Communications.

[18]  Z. Dong,et al.  Targeting integrin αvβ3 with indomethacin inhibits patient‐derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma , 2021, Clinical and translational medicine.

[19]  E. Hirsch,et al.  Phosphoproteomics Identifies PI3K Inhibitor–selective Adaptive Responses in Pancreatic Cancer Cell Therapy and Resistance , 2021, Molecular Cancer Therapeutics.

[20]  S. Macdonald,et al.  Emerging therapeutic opportunities for integrin inhibitors , 2021, Nature reviews. Drug discovery.

[21]  G. Giaccone,et al.  A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer , 2021, Frontiers in Oncology.

[22]  H. Cai,et al.  Protective function of interleukin‐22 in pulmonary fibrosis , 2021, Clinical and translational medicine.

[23]  W. Wang,et al.  Rebalancing TGF‐β/Smad7 signaling via Compound kushen injection in hepatic stellate cells protects against liver fibrosis and hepatocarcinogenesis , 2021, Clinical and translational medicine.

[24]  D. Andrews,et al.  MYC protein interactors in gene transcription and cancer , 2021, Nature Reviews Cancer.

[25]  Afsar U. Ahmed,et al.  A Potential Role for Integrin-Linked Kinase in Colorectal Cancer Growth and Progression via Regulating Senescence and Immunity , 2021, Frontiers in Genetics.

[26]  Lin Shijie,et al.  Deregulation of CLTC interacts with TFG, facilitating osteosarcoma via the TGF‐beta and AKT/mTOR signaling pathways , 2021, Clinical and translational medicine.

[27]  S. Mousa,et al.  New Thyrointegrin αvβ3 Antagonist with a Scalable Synthesis, Brain Penetration, and Potent Activity against Glioblastoma Multiforme. , 2021, Journal of medicinal chemistry.

[28]  T. Brümmendorf,et al.  Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial , 2021, International Journal of Hematology.

[29]  P. Zinzani,et al.  Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2021, The Lancet. Oncology.

[30]  P. Ghosh,et al.  Discovery of antiproliferative and anti-FAK inhibitory activity of 1,2,4-triazole derivatives containing acetamido carboxylic acid skeleton. , 2021, Bioorganic & medicinal chemistry letters.

[31]  M. Falasca,et al.  Exosomal integrins and their influence on pancreatic cancer progression and metastasis. , 2021, Cancer letters.

[32]  E. Giovannetti,et al.  Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma , 2021, Journal of experimental & clinical cancer research : CR.

[33]  Q. Ding,et al.  Integrin αvβ3 Engagement Regulates Glucose Metabolism and Migration through Focal Adhesion Kinase (FAK) and Protein Arginine Methyltransferase 5 (PRMT5) in Glioblastoma Cells , 2021, Cancers.

[34]  K. Okumura,et al.  The Multifaceted Roles of EGFL7 in Cancer and Drug Resistance , 2021, Cancers.

[35]  M. Shimaoka,et al.  Integrin Regulation in Immunological and Cancerous Cells and Exosomes , 2021, International journal of molecular sciences.

[36]  Rongqian Wu,et al.  Milk fat globule EGF factor 8 restores mitochondrial function via integrin‐medicated activation of the FAK‐STAT3 signaling pathway in acute pancreatitis , 2021, Clinical and translational medicine.

[37]  M. Karin,et al.  Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age? , 2021, Nature Reviews Clinical Oncology.

[38]  K. Pantel,et al.  Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions , 2021, Oncogene.

[39]  Jiang Ren,et al.  Targeting TGFβ signal transduction for cancer therapy , 2021, Signal Transduction and Targeted Therapy.

[40]  Yinying Wu,et al.  Thrombospondin 4/integrin α2/HSF1 axis promotes proliferation and cancer stem-like traits of gallbladder cancer by enhancing reciprocal crosstalk between cancer-associated fibroblasts and tumor cells , 2021, Journal of experimental & clinical cancer research : CR.

[41]  Guoping Wang,et al.  Src acts as the target of matrine to inhibit the proliferation of cancer cells by regulating phosphorylation signaling pathways , 2020, Cell Death & Disease.

[42]  H. Kodama,et al.  Induction of cellular senescence in fibroblasts through β1-integrin activation by tenascin-C-derived peptide and its protumor effect. , 2021, American journal of cancer research.

[43]  A. Giobbie-Hurder,et al.  Integrin αvβ6-TGFβ-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer. , 2020, Cancer cell.

[44]  M. Aghaei,et al.  Integrin α2β1 inhibition attenuates prostate cancer cell proliferation by cell cycle arrest, promoting apoptosis and reducing epithelial–mesenchymal transition , 2020, Journal of cellular physiology.

[45]  Jianbing Hou,et al.  The Roles of Integrin α5β1 in Human Cancer , 2020, OncoTargets and therapy.

[46]  Guangyu Liu,et al.  Pregnancy‐specific glycoprotein 9 acts as both a transcriptional target and a regulator of the canonical TGF‐β/Smad signaling to drive breast cancer progression , 2020, Clinical and translational medicine.

[47]  U. Reuning,et al.  Constitutive activation of integrin αvβ3 contributes to anoikis resistance of ovarian cancer cells , 2020, Molecular oncology.

[48]  P. ten Dijke,et al.  TGF‐β signaling in liver metastasis , 2020, Clinical and translational medicine.

[49]  Keqiu Jiang,et al.  Exosome-derived ENO1 regulates integrin α6β4 expression and promotes hepatocellular carcinoma growth and metastasis , 2020, Cell Death & Disease.

[50]  Lynette M. Smith,et al.  Secretory Mucin 5AC Promotes Neoplastic Progression by Augmenting KLF4-Mediated Pancreatic Cancer Cell Stemness , 2020, Cancer Research.

[51]  Robin T. Varghese,et al.  Connexin 43 confers chemoresistance through activating PI3K , 2020, bioRxiv.

[52]  M. Ruíz-Borrego,et al.  EDIL3 promotes epithelial–mesenchymal transition and paclitaxel resistance through its interaction with integrin αVβ3 in cancer cells , 2020, Cell Death Discovery.

[53]  Ping-Chih Ho,et al.  Lactate modulation of immune responses in inflammatory versus tumour microenvironments , 2020, Nature Reviews Immunology.

[54]  Y. Inagaki,et al.  Metabolic reprogramming sustains cancer cell survival following extracellular matrix detachment , 2020, Redox biology.

[55]  J. Ajani,et al.  Extracellular Vesicles from Cancer-Associated Fibroblasts Containing Annexin A6 Induces FAK-YAP Activation by Stabilizing β1 Integrin, Enhancing Drug Resistance , 2020, Cancer Research.

[56]  S. Mousa,et al.  Dual Targeting of Norepinephrine Transporter (NET) Function and Thyrointegrin αvβ3 Receptors in the Treatment of Neuroblastoma. , 2020, Journal of medicinal chemistry.

[57]  F. Prósper,et al.  Upregulated expression and function of the α4β1 integrin in multiple myeloma cells resistant to bortezomib , 2020, The Journal of pathology.

[58]  Á. Illés,et al.  ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  H. Rugo,et al.  Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  J. Niu,et al.  Integrin αvβ8 serves as a Novel Marker of Poor Prognosis in Colon Carcinoma and Regulates Cell Invasiveness through the Activation of TGF-β1 , 2020, Journal of Cancer.

[61]  A. Pandiella,et al.  Integrin ανβ6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis , 2020, Molecular Diagnosis & Therapy.

[62]  Yan Fu,et al.  Secreted Pyruvate Kinase M2 Promotes Lung Cancer Metastasis through Activating the Integrin Beta1/FAK Signaling Pathway. , 2020, Cell reports.

[63]  B. Kamińska,et al.  Integrin Signaling in Glioma Pathogenesis: From Biology to Therapy , 2020, International journal of molecular sciences.

[64]  Handong Ma,et al.  Periostin Promotes Colorectal Tumorigenesis through Integrin-FAK-Src Pathway-Mediated YAP/TAZ Activation. , 2020, Cell reports.

[65]  I. Waizenegger,et al.  T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity , 2020, eLife.

[66]  R. Shao,et al.  A novel biphenyl compound IMB-S7 ameliorates hepatic fibrosis in BDL rats by suppressing Sp1-mediated integrin αv expression , 2020, Acta Pharmacologica Sinica.

[67]  E. Hurt,et al.  Integrin β4-targeted cancer immunotherapies inhibit tumor growth and decrease metastasis. , 2019, Cancer research.

[68]  B. Seliger.  Basis of PD1/PD-L1 Therapies , 2019, Journal of clinical medicine.

[69]  M. Nolte,et al.  Controlling Immunity and Inflammation through Integrin-Dependent Regulation of TGF-β. , 2019, Trends in cell biology.

[70]  A. Steinle,et al.  Impairment of NKG2D-Mediated Tumor Immunity by TGF-β , 2019, Front. Immunol..

[71]  Ping Yang,et al.  Integrin α9 depletion promotes β‐catenin degradation to suppress triple‐negative breast cancer tumor growth and metastasis , 2019, International journal of cancer.

[72]  Qiaojun He,et al.  Deubiquitinating enzyme USP10 promotes hepatocellular carcinoma metastasis through deubiquitinating and stabilizing Smad4 protein , 2019, Molecular oncology.

[73]  R. Postier,et al.  ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells. , 2019, Gastroenterology.

[74]  Marilyn M. Li,et al.  Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. , 2019, Lung cancer.

[75]  Huimin Shen,et al.  Interleukin-8 promotes integrin β3 upregulation and cell invasion through PI3K/Akt pathway in hepatocellular carcinoma , 2019, Journal of experimental & clinical cancer research : CR.

[76]  Renya Zhang,et al.  Interaction between laminin-5γ2 and integrin β1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins , 2019, Oncogene.

[77]  M. Bachmann,et al.  Cell Adhesion by Integrins. , 2019, Physiological reviews.

[78]  S. Jalkanen,et al.  68Ga-DOTA-E[c(RGDfK)]2 PET Imaging of SHARPIN-Regulated Integrin Activity in Mice , 2019, The Journal of Nuclear Medicine.

[79]  A. Félix,et al.  Arl13b Regulates Breast Cancer Cell Migration and Invasion by Controlling Integrin-Mediated Signaling , 2019, Cancers.

[80]  O. De Wever,et al.  Stromal integrin α11 regulates PDGFR-β signaling and promotes breast cancer progression. , 2019, The Journal of clinical investigation.

[81]  N. Cho,et al.  ITGB4-mediated metabolic reprogramming of cancer-associated fibroblasts , 2019, Oncogene.

[82]  A. Vannini,et al.  αvβ3-integrin regulates PD-L1 expression and is involved in cancer immune evasion , 2019, Proceedings of the National Academy of Sciences.

[83]  X. Xia,et al.  A DNA nano-device simultaneously activating the EGFR and integrin for enhancing cytoskeletal activity and cancer cell treatment. , 2019, Nano letters.

[84]  Hongzhuan Chen,et al.  Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer , 2019, Molecular Cancer Therapeutics.

[85]  M. Cominetti,et al.  Alphavbeta3 integrin blocking inhibits apoptosis and induces autophagy in murine breast tumor cells. , 2019, Biochimica et biophysica acta. Molecular cell research.

[86]  Jun Yu,et al.  Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity , 2019, Nature Microbiology.

[87]  Shanshan Liu,et al.  Potential Role of Exosomes in Cancer Metastasis , 2019, BioMed research international.

[88]  A. Molven,et al.  α11β1 Integrin is Induced in a Subset of Cancer-Associated Fibroblasts in Desmoplastic Tumor Stroma and Mediates In Vitro Cell Migration , 2019, Cancers.

[89]  K. Lim,et al.  Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion , 2019, Gut.

[90]  M. Tsao,et al.  LOXL1 Is Regulated by Integrin α11 and Promotes Non-Small Cell Lung Cancer Tumorigenicity , 2019, Cancers.

[91]  Eduard Batlle,et al.  Transforming Growth Factor-β Signaling in Immunity and Cancer. , 2019, Immunity.

[92]  S. Nelander,et al.  Integrin α10, a Novel Therapeutic Target in Glioblastoma, Regulates Cell Migration, Proliferation, and Survival , 2019, Cancers.

[93]  G. Mills,et al.  Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. , 2019, The Lancet. Oncology.

[94]  R. Iozzo,et al.  Prostate cancer sheds the αvβ3 integrin in vivo through exosomes. , 2019, Matrix biology : journal of the International Society for Matrix Biology.

[95]  H. Ji,et al.  Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin &bgr;1 , 2019, The Journal of clinical investigation.

[96]  N. Pavlakis,et al.  Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  Xinran Tang,et al.  NFAT1 Hypermethylation Promotes Epithelial-Mesenchymal Transition and Metastasis in Nasopharyngeal Carcinoma by Activating ITGA6 Transcription , 2019, Neoplasia.

[98]  P. Chanvorachote,et al.  Integrin as a Molecular Target for Anti-cancer Approaches in Lung Cancer , 2019, AntiCancer Research.

[99]  Dan Yang,et al.  Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β3-p38 MAPK signalling. , 2019, Cancer letters.

[100]  Binbin Ma,et al.  Reciprocal regulation of integrin β4 and KLF4 promotes gliomagenesis through maintaining cancer stem cell traits , 2019, Journal of experimental & clinical cancer research : CR.

[101]  Y. Açil,et al.  A comparative assessment of the effects of integrin inhibitor cilengitide on primary culture of head and neck squamous cell carcinoma (HNSCC) and HNSCC cell lines , 2019, Clinical and Translational Oncology.

[102]  M. Varjosalo,et al.  Talin-mediated force transmission and talin rod domain unfolding independently regulate adhesion signaling , 2019, Journal of Cell Science.

[103]  Yibin Kang,et al.  Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling. , 2019, Cancer cell.

[104]  K. Song,et al.  A Transforming Growth Factor‐β and H19 Signaling Axis in Tumor‐Initiating Hepatocytes That Regulates Hepatic Carcinogenesis , 2018, Hepatology.

[105]  Yue Zhang,et al.  FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation , 2018, Cancer biology & therapy.

[106]  H. Hirte,et al.  Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies , 2019, Targeted Oncology.

[107]  C. Brakebusch,et al.  The Interaction between Laminin-332 and α3β1 Integrin Determines Differentiation and Maintenance of CAFs, and Supports Invasion of Pancreatic Duct Adenocarcinoma Cells , 2018, Cancers.

[108]  R. Merino,et al.  TGFβ Superfamily Members as Regulators of B Cell Development and Function—Implications for Autoimmunity , 2018, International journal of molecular sciences.

[109]  J. Tolson,et al.  A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098 , 2018, Neuro-oncology.

[110]  F. Kuonen,et al.  TGFβ, Fibronectin and Integrin α5β1 Promote Invasion in Basal Cell Carcinoma. , 2018, Journal of Investigative Dermatology.

[111]  Jie Lin,et al.  IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma , 2018, Oncogene.

[112]  Yifan Cheng,et al.  Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells. , 2018, JCI insight.

[113]  Shelly R. Peyton,et al.  Integrin α6 and EGFR signaling converge at mechanosensitive calpain 2. , 2018, Biomaterials.

[114]  R. Schiff,et al.  AhR ligand aminoflavone suppresses α6‐integrin–Src–Akt signaling to attenuate tamoxifen resistance in breast cancer cells , 2018, Journal of cellular physiology.

[115]  H. Einsele,et al.  CAR T cells targeting αvβ3 integrin are effective against advanced cancer in preclinical models , 2018, Advances in cell and gene therapy.

[116]  Jianping Zhou,et al.  A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy. , 2018, Acta biomaterialia.

[117]  Tien-Huang Lin,et al.  Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin α4β1 system. , 2018, Cancer letters.

[118]  M. Loh,et al.  Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  W. Hong,et al.  Rab34 regulates adhesion, migration, and invasion of breast cancer cells , 2018, Oncogene.

[120]  John C. Dawson,et al.  Kindlin-1 Promotes Pulmonary Breast Cancer Metastasis. , 2018, Cancer research.

[121]  Kwang Ho Kim,et al.  Epidermal growth factor-mediated Rab25 pathway regulates integrin β1 trafficking in colon cancer , 2018, Cancer Cell International.

[122]  Y. Huang,et al.  14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling , 2018, Journal of experimental & clinical cancer research : CR.

[123]  L. Gan,et al.  Extracellular matrix protein 1 promotes cell metastasis and glucose metabolism by inducing integrin β4/FAK/SOX2/HIF-1α signaling pathway in gastric cancer , 2018, Oncogene.

[124]  Jiang Yu,et al.  The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network , 2018, The Journal of clinical investigation.

[125]  J. Mazières,et al.  Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study. , 2017, Clinical lung cancer.

[126]  Jae-Seon Lee,et al.  Integrin α6β4-Src-AKT signaling induces cellular senescence by counteracting apoptosis in irradiated tumor cells and tissues , 2018, Cell Death & Differentiation.

[127]  Rolando Vegliante,et al.  Tenascin-C Promotes Tumor Cell Migration and Metastasis through Integrin α9β1-Mediated YAP Inhibition. , 2018, Cancer research.

[128]  A. Puisieux,et al.  Pleiotropic Roles for ZEB1 in Cancer. , 2018, Cancer research.

[129]  B. Sritularak,et al.  Phoyunnanin E inhibits migration of non-small cell lung cancer cells via suppression of epithelial-to-mesenchymal transition and integrin αv and integrin β3 , 2017, BMC Complementary and Alternative Medicine.

[130]  W. Ciszewski,et al.  The ILK-MMP9-MRTF axis is crucial for EndMT differentiation of endothelial cells in a tumor microenvironment. , 2017, Biochimica et biophysica acta. Molecular cell research.

[131]  G. Fuller,et al.  Glioblastoma stem cells exploit the αvβ8 integrin-TGFβ1 signaling axis to drive tumor initiation and progression , 2017, Oncogene.

[132]  S. Richon,et al.  Cancer-associated fibroblasts lead tumor invasion through integrin-β3–dependent fibronectin assembly , 2017, The Journal of cell biology.

[133]  K. Pienta,et al.  Tenascin-C and Integrin α9 Mediate Interactions of Prostate Cancer with the Bone Microenvironment. , 2017, Cancer research.

[134]  Yinghui Zhu,et al.  ANGPTL1 Interacts with Integrin α1β1 to Suppress HCC Angiogenesis and Metastasis by Inhibiting JAK2/STAT3 Signaling. , 2017, Cancer research.

[135]  P. Foubert,et al.  PI3Kγ Activates Integrin α4 and Promotes Immune Suppressive Myeloid Cell Polarization during Tumor Progression , 2017, Cancer Immunology Research.

[136]  J. Beaulieu,et al.  Involvement of the Integrin α1β1 in the Progression of Colorectal Cancer , 2017, Cancers.

[137]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[138]  James L. Gulley,et al.  A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells , 2017, Oncoimmunology.

[139]  Zhongming Zhao,et al.  Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. , 2017, Cancer research.

[140]  Z. Liu,et al.  FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation , 2017, Oncogene.

[141]  Rohini Sharma,et al.  Breast cancer metastasis: Putative therapeutic role of vascular cell adhesion molecule-1 , 2017, Cellular Oncology.

[142]  V. Yang,et al.  Krüppel-like factor 4 (KLF4): What we currently know. , 2017, Gene.

[143]  M. Goetz,et al.  A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors , 2017, Cancer Chemotherapy and Pharmacology.

[144]  Y-S Kim,et al.  Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin β1-driven Src-Akt bypass signaling , 2017, Oncogene.

[145]  Lingqiang Zhang,et al.  Smurf1 inhibits integrin activation by controlling Kindlin-2 ubiquitination and degradation , 2017, The Journal of cell biology.

[146]  B. Mellado,et al.  Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. , 2017, European journal of cancer.

[147]  J. Hung,et al.  Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1 , 2017, Oncogene.

[148]  M. Sheetz,et al.  EGFR and HER2 Activate Rigidity Sensing Only on Rigid Matrices , 2017, Nature materials.

[149]  Y. Takada,et al.  Crosstalk between insulin-like growth factor (IGF) receptor and integrins through direct integrin binding to IGF1. , 2017, Cytokine & growth factor reviews.

[150]  T. Curiel,et al.  Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ Treg cells are a source of tumour-associated Treg cells , 2017, Nature Communications.

[151]  Jeffrey A Jones,et al.  Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. , 2017, The Lancet. Haematology.

[152]  Xinran Tang,et al.  HOPX hypermethylation promotes metastasis via activating SNAIL transcription in nasopharyngeal carcinoma , 2017, Nature Communications.

[153]  P. Weinreb,et al.  Fibronectin-guided migration of carcinoma collectives , 2017, Nature Communications.

[154]  S. Violette,et al.  Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[155]  Dustin R. Bunch,et al.  Identification of Filamin-A and -B as potential biomarkers for prostate cancer , 2016, Future science OA.

[156]  L. Lau,et al.  CCN2 induces cellular senescence in fibroblasts , 2017, Journal of Cell Communication and Signaling.

[157]  C. Kerr,et al.  Transglutaminase Interaction with α6/β4-Integrin Stimulates YAP1-Dependent ΔNp63α Stabilization and Leads to Enhanced Cancer Stem Cell Survival and Tumor Formation. , 2016, Cancer research.

[158]  K. Gibson-Corley,et al.  α3β1 Integrin Suppresses Prostate Cancer Metastasis via Regulation of the Hippo Pathway. , 2016, Cancer research.

[159]  Yi Fu,et al.  The E3 ubiquitin ligase c-Cbl mediates integrin β1 ubiquitination during dilated cardiomyopathy. , 2016, Biochemical and biophysical research communications.

[160]  Xiao-Qing Li,et al.  RUNX2 promotes breast cancer bone metastasis by increasing integrin α5-mediated colonization. , 2016, Cancer letters.

[161]  Gang Wu,et al.  Integrin α6/Akt/Erk signaling is essential for human breast cancer resistance to radiotherapy , 2016, Scientific Reports.

[162]  M. Freund,et al.  Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9. , 2016, JCI insight.

[163]  D. Jain,et al.  αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor. , 2016, Cancer research.

[164]  S. Batra,et al.  MUC5AC interactions with integrin β4 enhances the migration of lung cancer cells through FAK signaling , 2016, Oncogene.

[165]  M. Udey,et al.  MFG-E8 Drives Melanoma Growth by Stimulating Mesenchymal Stromal Cell-Induced Angiogenesis and M2 Polarization of Tumor-Associated Macrophages. , 2016, Cancer research.

[166]  T. Powles,et al.  A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[167]  Toshio Shimizu,et al.  A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors , 2016, Cancer Chemotherapy and Pharmacology.

[168]  C. Tahimic,et al.  Regulation of Ligand and Shear Stress-induced Insulin-like Growth Factor 1 (IGF1) Signaling by the Integrin Pathway* , 2016, The Journal of Biological Chemistry.

[169]  A. Lambacher,et al.  Kindlin-2 cooperates with talin to activate integrins and induces cell spreading by directly binding paxillin , 2016, eLife.

[170]  Raphael Ruppert,et al.  The kindlin family: functions, signaling properties and implications for human disease , 2016, Journal of Cell Science.

[171]  N. Etienne-Selloum,et al.  Integrin α5β1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma , 2015, Cell Death and Differentiation.

[172]  I Jurisica,et al.  Integrin α11β1 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer , 2015, Oncogene.

[173]  J. Beaulieu,et al.  Integrin α1β1 expression is controlled by c-MYC in colorectal cancer cells , 2015, Oncogene.

[174]  F. Aoudjit,et al.  Alpha2beta1 integrin in cancer development and chemoresistance. , 2015, Seminars in cancer biology.

[175]  D. Cheresh,et al.  Glioblastomas require integrin αvβ3/PAK4 signaling to escape senescence. , 2015, Cancer research.

[176]  M. Sheetz,et al.  Integrin-beta3 clusters recruit clathrin-mediated endocytic machinery in the absence of traction force , 2015, Nature Communications.

[177]  Gary K. Schwartz,et al.  Tumour exosome integrins determine organotropic metastasis , 2015, Nature.

[178]  J. Takagi,et al.  Interplay of Endosomal pH and Ligand Occupancy in Integrin α5β1 Ubiquitination, Endocytic Sorting, and Cell Migration. , 2015, Cell reports.

[179]  E. Nice,et al.  Integrin αvβ6 sets the stage for colorectal cancer metastasis , 2015, Cancer and Metastasis Reviews.

[180]  Chuanqing Zhou,et al.  Photo-thermal effect enhances the efficiency of radiotherapy using Arg-Gly-Asp peptides-conjugated gold nanorods that target αvβ3 in melanoma cancer cells , 2015, Journal of Nanobiotechnology.

[181]  E. Li,et al.  Loss of miR-200b promotes invasion via activating the Kindlin-2/integrin β1/AKT pathway in esophageal squamous cell carcinoma: An E-cadherin-independent mechanism , 2015, Oncotarget.

[182]  J. Milanowski,et al.  Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[183]  Jie Yuan,et al.  Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways , 2015, Oncotarget.

[184]  Prahlad T. Ram,et al.  The ZNF304-integrin axis protects against anoikis in cancer , 2015, Nature Communications.

[185]  Michael A. Hollingsworth,et al.  Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver , 2015, Nature Cell Biology.

[186]  J. Worthington,et al.  Integrin αvβ8-Mediated TGF-β Activation by Effector Regulatory T Cells Is Essential for Suppression of T-Cell-Mediated Inflammation , 2015, Immunity.

[187]  T. Mikkelsen,et al.  Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. , 2015, Neuro-oncology.

[188]  Erik Sahai,et al.  Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling , 2015, Cancer cell.

[189]  Sheng Li,et al.  Krüppel-like Factor 4 Promotes Esophageal Squamous Cell Carcinoma Differentiation by Up-regulating Keratin 13 Expression* , 2015, The Journal of Biological Chemistry.

[190]  J. Qin,et al.  Structural mechanism of integrin inactivation by filamin , 2015, Nature Structural &Molecular Biology.

[191]  A. Claing,et al.  ARF1 regulates adhesion of MDA-MB-231 invasive breast cancer cells through formation of focal adhesions. , 2015, Cellular signalling.

[192]  A. Berman,et al.  Implication of α2β1 integrin in anoikis of MCF-7 human breast carcinoma cells , 2015, Biochemistry (Moscow).

[193]  A. Ashton,et al.  Exosomes: Mechanisms of Uptake , 2015, Journal of circulating biomarkers.

[194]  N. Gammoh,et al.  MicroRNA-26a promotes anoikis in human hepatocellular carcinoma cells by targeting alpha5 integrin , 2014, Oncotarget.

[195]  J. Olson,et al.  A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. , 2013, Neuro-oncology.

[196]  C. Bokemeyer,et al.  Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[197]  H. Hurwitz,et al.  A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors , 2015, Cancer Chemotherapy and Pharmacology.

[198]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[199]  S. Goodman,et al.  Integrins αvβ3 and αvβ5 as prognostic, diagnostic, and therapeutic targets in gastric cancer , 2014, Gastric Cancer.

[200]  S. Corbett,et al.  The fate of internalized α5 integrin is regulated by matrix-capable fibronectin. , 2014, The Journal of surgical research.

[201]  K. Aldape,et al.  Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[202]  Sanjay Kumar,et al.  Microenvironmental Stiffness Enhances Glioma Cell Proliferation by Stimulating Epidermal Growth Factor Receptor Signaling , 2014, PloS one.

[203]  Rhian Gabe,et al.  Therapeutic Targeting of Integrin αvβ6 in Breast Cancer , 2014, Journal of the National Cancer Institute.

[204]  Kuan-song Wang,et al.  Epidermal Growth Factor-Like Domain-Containing Protein 7 (EGFL7) Enhances EGF Receptor−AKT Signaling, Epithelial−Mesenchymal Transition, and Metastasis of Gastric Cancer Cells , 2014, PloS one.

[205]  J. Lakins,et al.  Oncogenic targeting of BRM drives malignancy through C/EBPβ-dependent induction of α5 integrin , 2014, Oncogene.

[206]  M. Wirth,et al.  A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy. , 2014, European urology.

[207]  Jing Wang,et al.  An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition , 2014, Nature Cell Biology.

[208]  B. Ring,et al.  Nuclear SIPA1 activates integrin β1 promoter and promotes invasion of breast cancer cells , 2014, Oncogene.

[209]  S. Oehninger,et al.  Role for the endometrial epithelial protein MFG-E8 and its receptor integrin αvβ3 in human implantation: results of an in vitro trophoblast attachment study using established human cell lines. , 2014, Fertility and sterility.

[210]  T. Brümmendorf,et al.  Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part) , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[211]  Michael J. O'Donovan,et al.  The transcription factor IRF8 activates integrin-mediated TGF-β signaling and promotes neuroinflammation. , 2014, Immunity.

[212]  A. Jazaeri,et al.  Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin. , 2014, Gynecologic oncology.

[213]  A. Chakravarti,et al.  In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines , 2013, Radiation oncology.

[214]  M. Malbouyres,et al.  CCM1–ICAP-1 complex controls β1 integrin–dependent endothelial contractility and fibronectin remodeling , 2013, The Journal of cell biology.

[215]  Chae-Yong Kim,et al.  Combination therapy of cilengitide with belotecan against experimental glioblastoma , 2013, International journal of cancer.

[216]  N. Giese,et al.  Tspan8, CD44v6 and alpha6beta4 are biomarkers of migrating pancreatic cancer‐initiating cells , 2013, International journal of cancer.

[217]  J. Pouwels,et al.  Integrin inactivators: balancing cellular functions in vitro and in vivo , 2013, Nature Reviews Molecular Cell Biology.

[218]  E. Chavakis,et al.  EGFL7 ligates αvβ3 integrin to enhance vessel formation. , 2013, Blood.

[219]  L. Shaw,et al.  GLI1 regulates a novel neuropilin-2/α6β1 integrin based autocrine pathway that contributes to breast cancer initiation , 2013, EMBO molecular medicine.

[220]  W. Gradishar,et al.  Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 , 2013, Clinical Cancer Research.

[221]  M. Dontenwill,et al.  Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors , 2013, Cancers.

[222]  S. Goodman,et al.  Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression , 2013, Virchows Archiv.

[223]  J. Soria,et al.  Annals of Oncology , 2022 .

[224]  R. Svensson,et al.  Integrin α3β1 regulates tumor cell responses to stromal cells and can function to suppress prostate cancer metastatic colonization , 2013, Clinical & Experimental Metastasis.

[225]  J. Beaulieu,et al.  Integrin α1 subunit is up-regulated in colorectal cancer , 2013, Biomarker Research.

[226]  C. Tepper,et al.  Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization. , 2012, Endocrine-related cancer.

[227]  S. Cox,et al.  Cdc42 promotes transendothelial migration of cancer cells through β1 integrin , 2012, The Journal of cell biology.

[228]  V. Préat,et al.  RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. , 2012, Molecular pharmaceutics.

[229]  S. Froelich,et al.  Involvement of the TGFβ pathway in the regulation of α5β1 integrins by caveolin‐1 in human glioblastoma , 2012, International journal of cancer.

[230]  C. Ng,et al.  A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma , 2012, Melanoma research.

[231]  J. Godet,et al.  Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma. , 2012, Cancer research.

[232]  H. Shirato,et al.  Rab5c promotes AMAP1–PRKD2 complex formation to enhance β1 integrin recycling in EGF-induced cancer invasion , 2012, The Journal of cell biology.

[233]  D. Camidge,et al.  Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[234]  D. Radisky,et al.  MYC Suppresses Cancer Metastasis by Direct Transcriptional Silencing of αv and β3 Integrin Subunits , 2012, Nature Cell Biology.

[235]  A. Shevchenko,et al.  β₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. , 2012, The Journal of clinical investigation.

[236]  F. Sigaux,et al.  α2β1 Integrin Promotes Chemoresistance against Doxorubicin in Cancer Cells through Extracellular Signal-regulated Kinase (ERK)* , 2012, The Journal of Biological Chemistry.

[237]  C. Belani,et al.  Volociximab in cancer , 2012, Expert opinion on biological therapy.

[238]  Pang-Kuo Lo,et al.  CD49f and CD61 identify Her2/neu-induced mammary tumor initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling , 2011, Oncogene.

[239]  Carlos L. Arteaga,et al.  Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.

[240]  C. Hudis,et al.  A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[241]  O. Kallioniemi,et al.  SHARPIN is an endogenous inhibitor of β1-integrin activation , 2011, Nature Cell Biology.

[242]  M. Papotti,et al.  β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells , 2011, Oncogene.

[243]  C. DiPersio,et al.  Integrin α3β1 as a breast cancer target , 2011, Expert opinion on therapeutic targets.

[244]  S. Hilsenbeck,et al.  β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib , 2011, Breast Cancer Research.

[245]  T. Mikkelsen,et al.  Cilengitide induces autophagy-mediated cell death in glioma cells. , 2011, Neuro-oncology.

[246]  D. Schadendorf,et al.  A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma , 2011, British Journal of Cancer.

[247]  P. Foubert,et al.  Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. , 2011, Cancer cell.

[248]  E. Lengyel,et al.  A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. , 2011, Gynecologic oncology.

[249]  Nikolina Radulovich,et al.  Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer , 2011, Proceedings of the National Academy of Sciences.

[250]  Emmett V Schmidt,et al.  The integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers. , 2011, Cancer research.

[251]  Ben Fabry,et al.  Integrin α5β1 facilitates cancer cell invasion through enhanced contractile forces , 2011, Journal of Cell Science.

[252]  M. Ratain,et al.  A phase I study of continuous infusion cilengitide in patients with solid tumors , 2012, Investigational new drugs.

[253]  S. Alahari,et al.  Integrin-mediated function of Rab GTPases in cancer progression , 2010, Molecular Cancer.

[254]  H. Stenmark,et al.  Ubiquitination of α-integrin cytoplasmic tails , 2010, Communicative & integrative biology.

[255]  S. Knox,et al.  Cancer esearch apeutics , Targets , and Chemical Biology i – α v Integrin Monoclonal Antibody Intetumumab Enhances Efficacy of Radiation Therapy and Reduces Metastasis R uman Cancer Xenografts in Nude Rats , 2010 .

[256]  A. Cress,et al.  The laminin binding integrin α6β1 in prostate cancer perineural invasion , 2010, Journal of cellular physiology.

[257]  L. Lau,et al.  The Matricellular Protein CCN1/CYR61 Induces Fibroblast Senescence and Restricts Fibrosis in Cutaneous Wound Healing , 2010, Nature Cell Biology.

[258]  R. McLendon,et al.  Integrin alpha 6 regulates glioblastoma stem cells. , 2010, Cell stem cell.

[259]  J. Sosman,et al.  A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma , 2010, Cancer.

[260]  A. Richmond,et al.  Chemokines and chemokine receptors: new insights into cancer-related inflammation. , 2010, Trends in molecular medicine.

[261]  Feng Gao,et al.  RGD-conjugated dendrimer-modified gold nanorods for in vivo tumor targeting and photothermal therapy. , 2010, Molecular pharmaceutics.

[262]  J. Roman,et al.  alpha5beta1-integrin expression is essential for tumor progression in experimental lung cancer. , 2010, American journal of respiratory cell and molecular biology.

[263]  S. Stilgenbauer,et al.  Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. , 2009, Blood.

[264]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[265]  P. Fortina,et al.  The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma , 2009, Cell cycle.

[266]  A. Sood,et al.  Combined anti-angiogenic therapy against VEGF and integrin alphabeta in an orthotopic model of ovarian cancer , 2009, Cancer biology & therapy.

[267]  J. Norman,et al.  Integrins: masters and slaves of endocytic transport , 2009, Nature Reviews Molecular Cell Biology.

[268]  M. Brizzi,et al.  Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression. , 2009, Cancer research.

[269]  Stephen L. Brown,et al.  Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule‐dependency , 2009, International journal of cancer.

[270]  E. Kremmer,et al.  SCAI acts as a suppressor of cancer cell invasion through the transcriptional control of β1-integrin , 2009, Nature Cell Biology.

[271]  C. Bokemeyer,et al.  Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway , 2008, Journal of experimental & clinical cancer research : CR.

[272]  A. Tolcher,et al.  Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study , 2008, Clinical Cancer Research.

[273]  T. Mikkelsen,et al.  Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[274]  Liz Y. Han,et al.  Tumor-selective response to antibody-mediated targeting of αvβ3 integrin in ovarian cancer , 2008 .

[275]  L. Del Valle,et al.  Angiostatic activity of obtustatin as α1β1 integrin inhibitor in experimental melanoma growth , 2008, International journal of cancer.

[276]  Gordon C K Roberts,et al.  Structural basis for the interaction between the cytoplasmic domain of the hyaluronate receptor layilin and the talin F3 subdomain. , 2008, Journal of molecular biology.

[277]  R. Kerbel,et al.  Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. , 2008, Cancer cell.

[278]  T. Ueda,et al.  The Regulatory RAB and ARF GTPases for Vesicular Trafficking1[W] , 2008, Plant Physiology.

[279]  Xiwu Chen,et al.  Loss of integrin alpha1beta1 ameliorates Kras-induced lung cancer. , 2008, Cancer research.

[280]  Mina J Bissell,et al.  Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. , 2008, Cancer research.

[281]  Yuelei Shen,et al.  TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function , 2008, Nature.

[282]  T. MacDonald,et al.  Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[283]  A. Levine,et al.  TGF-β Inhibits IL-2 Production and Promotes Cell Cycle Arrest in TCR-Activated Effector/Memory T Cells in the Presence of Sustained TCR Signal Transduction1 , 2008, The Journal of Immunology.

[284]  K. Furuuchi,et al.  Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer , 2008, Nature Immunology.

[285]  A. Grichine,et al.  Cell adaptive response to extracellular matrix density is controlled by ICAP-1–dependent β1-integrin affinity , 2008, The Journal of cell biology.

[286]  E. Raymond,et al.  Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors , 2008, Investigational New Drugs.

[287]  G. Mills,et al.  Rab25 associates with α5β1 integrin to promote invasive migration in 3D microenvironments , 2007 .

[288]  D. Clemmons,et al.  Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer , 2007, Nature Reviews Drug Discovery.

[289]  R. Alon,et al.  Integrin modulation and signaling in leukocyte adhesion and migration , 2007, Immunological reviews.

[290]  I. Jurisica,et al.  Integrin α11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells , 2007, Proceedings of the National Academy of Sciences.

[291]  Benjamin D. Sachs,et al.  Fibrinogen inhibits neurite outgrowth via β3 integrin-mediated phosphorylation of the EGF receptor , 2007, Proceedings of the National Academy of Sciences.

[292]  A. Gorter,et al.  Overexpression of the αvβ6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival , 2007 .

[293]  Michael J. McGuire,et al.  A Peptide Selected by Biopanning Identifies the Integrin αvβ6 as a Prognostic Biomarker for Nonsmall Cell Lung Cancer , 2007 .

[294]  Xiaojing Ye,et al.  The integrins , 2007, Genome Biology.

[295]  Kenneth Leslie,et al.  Constitutively Activated Stat3 Induces Tumorigenesis and Enhances Cell Motility of Prostate Epithelial Cells through Integrin β6 , 2007, Molecular and Cellular Biology.

[296]  M. Bouvet,et al.  Determination of the Ligand-Binding Specificities of the &agr;2&bgr;1 and &agr;1&bgr;1 Integrins in a Novel 3-Dimensional In Vitro Model of Pancreatic Cancer , 2007, Pancreas.

[297]  C. Napoli,et al.  Cooperation between Myc and YY1 provides novel silencing transcriptional targets of α3β1-integrin in tumour cells , 2007, Oncogene.

[298]  P. Monzo,et al.  The Rab4A Effector Protein Rabip4 Is Involved in Migration of NIH 3T3 Fibroblasts* , 2006, Journal of Biological Chemistry.

[299]  G. Inghirami,et al.  β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis , 2006, Cell.

[300]  N. Fox,et al.  Blocking the alpha 4 integrin-paxillin interaction selectively impairs mononuclear leukocyte recruitment to an inflammatory site. , 2006, The Journal of clinical investigation.

[301]  I. Campbell,et al.  The molecular basis of filamin binding to integrins and competition with talin. , 2006, Molecular cell.

[302]  M. Jinnin,et al.  Increased Expression of Integrin αvβ5 Induces the Myofibroblastic Differentiation of Dermal Fibroblasts , 2006 .

[303]  J. Norman,et al.  Integrin Trafficking and the Control of Cell Migration , 2006, Traffic.

[304]  R. Dubridge,et al.  Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. , 2006, Journal of experimental therapeutics & oncology.

[305]  D. Ribatti,et al.  Biological and molecular properties of a new αvβ3/αvβ5 integrin antagonist , 2005, Molecular Cancer Therapeutics.

[306]  J. Beaulieu,et al.  Upregulation of a functional form of the β4 integrin subunit in colorectal cancers correlates with c-Myc expression , 2005, Oncogene.

[307]  P. Marie,et al.  Cbl-mediated ubiquitination of α5 integrin subunit mediates fibronectin-dependent osteoblast detachment and apoptosis induced by FGFR2 activation , 2005, Journal of Cell Science.

[308]  D. A. Hanson,et al.  Focal adhesion kinase: in command and control of cell motility , 2005, Nature Reviews Molecular Cell Biology.

[309]  D. Sheppard.  Roles of αv integrins in vascular biology and pulmonary pathology , 2004 .

[310]  P. Newman,et al.  Integrins: dynamic scaffolds for adhesion and signaling in platelets. , 2004, Blood.

[311]  M. Trikha,et al.  CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo , 2004, International journal of cancer.

[312]  Didier Y. R. Stainier,et al.  The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation , 2004, Nature.

[313]  L. Chung,et al.  Modulation of prostate cancer growth in bone microenvironments , 2004, Journal of cellular biochemistry.

[314]  M. Fornaro,et al.  Integrins and Prostate Cancer Metastases , 2004, Cancer and Metastasis Reviews.

[315]  F. Soncin,et al.  VE‐statin, an endothelial repressor of smooth muscle cell migration , 2003, The EMBO journal.

[316]  E. Feldman,et al.  N-Myc overexpression leads to decreased β1 integrin expression and increased apoptosis in human neuroblastoma cells , 2003, Oncogene.

[317]  R. Fässler,et al.  Disruption of Focal Adhesions by Integrin Cytoplasmic Domain-associated Protein-1α* , 2003, The Journal of Biological Chemistry.

[318]  S. Barry,et al.  The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3. , 2003, The Biochemical journal.

[319]  R. Kalluri,et al.  Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. , 2003, Cancer research.

[320]  K. Ling,et al.  Type Iγ phosphatidylinositol phosphate kinase targets and regulates focal adhesions , 2002, Nature.

[321]  S. Szabo,et al.  The Transcription Factor T-bet Regulates Mucosal T Cell Activation in Experimental Colitis and Crohn's Disease , 2002, The Journal of experimental medicine.

[322]  D. Sheppard,et al.  The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP–dependent activation of TGF-β1 , 2002, The Journal of cell biology.

[323]  A. Nordheim,et al.  Serum response factor is crucial for actin cytoskeletal organization and focal adhesion assembly in embryonic stem cells , 2002, The Journal of cell biology.

[324]  K. Scott,et al.  Different Phenotypes in Human Prostate Cancer: α6 or α3 Integrin in Cell-extracellular Adhesion Sites , 2002 .

[325]  F. Aoudjit,et al.  Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells , 2001, Oncogene.

[326]  R. Flavell,et al.  Cutting Edge: TGF-β Inhibits Th Type 2 Development Through Inhibition of GATA-3 Expression , 2000, The Journal of Immunology.

[327]  T. Byzova,et al.  A mechanism for modulation of cellular responses to VEGF: activation of the integrins. , 2000, Molecular cell.

[328]  Semi Kim,et al.  Regulation of Angiogenesis in Vivo by Ligation of Integrin α5β1 with the Central Cell-Binding Domain of Fibronectin , 2000 .

[329]  P. Carmeliet.  Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[330]  W. Travis,et al.  A role for the integrin alphavbeta8 in the negative regulation of epithelial cell growth. , 2000, Cancer research.

[331]  S. Soddu,et al.  P53 Inhibits α6β4 Integrin Survival Signaling by Promoting the Caspase 3–Dependent Cleavage of Akt/PKB , 1999, The Journal of cell biology.

[332]  N. Kaminski,et al.  A Mechanism for Regulating Pulmonary Inflammation and Fibrosis: The Integrin αvβ6 Binds and Activates Latent TGF β1 , 1999, Cell.

[333]  E Ruoslahti,et al.  Integrin signaling. , 1999, Science.

[334]  D. Clemmons,et al.  Blocking ligand occupancy of the αVβ3 integrin inhibits insulin-like growth factor I signaling in vascular smooth muscle cells , 1998 .

[335]  D. Rifkin,et al.  Interactions between Growth Factors and Integrins: Latent Forms of Transforming Growth Factor-β Are Ligands for the Integrin αvβ1 , 1998 .

[336]  C. Der,et al.  The coupling of α6β4 integrin to Ras–MAP kinase pathways mediated by Shc controls keratinocyte proliferation , 1997 .

[337]  S. Isoe,et al.  Transforming Growth Factor-β Inhibits Interferon-γ Secretion by Lymph okine-activated Killer Cells Stimulated with Tumor Cells , 1996 .

[338]  J. Parsons,et al.  Interaction of Focal Adhesion Kinase with Cytoskeletal Protein Talin (*) , 1995, The Journal of Biological Chemistry.

[339]  M. Hemler,et al.  The pathophysiologic role of alpha 4 integrins in vivo. , 1994, The Journal of clinical investigation.